舒尼替尼药物中国专利分析  

Chinese patent analysis on Sunitinib

作　　者：齐悦如[1] 欧阳雪宇[1] 陈红霞[1] 张朝磊[1] 

机构地区：[1]国家知识产权局专利局专利审查协作北京中心,北京100086

出　　处：《中国医药导报》2015年第12期160-164,共5页China Medical Herald

摘　　要：本文通过对国内舒尼替尼药物专利申请量、申请人、技术主题进行研究，分析舒尼替尼专利的整体申请状况及可能产生的技术壁垒。研究发现，2001～2014年舒尼替尼的专利申请量在2007年达到高峰，但2010～2014年专利申请人数量与专利申请量均已经处于下降趋势。舒尼替尼专利申请的技术主题涉及化合物及其制备方法、组合物专利、制剂专利等，专利保护已经较全面。研发企业若想对舒尼替尼类药物继续进行专利保护，可从化合物的不同盐形式及其晶体、中间体制备和制剂等角度进行研发。In this article, Chinese patent situation and major technologly barrier of sunitinib was statistically analyzed. Some useful competitive information is throughly analyzed, such as aspects of patent application quantity, applicants and technical topics and so on. Finally, from 2001 to 2014, patent application quantity of Sunitinib comes to a peak on 2007, but the quantity of patent application and applicants go into slow growth period from 2010 to 2014. The technical topics of Sunitinib involves compound, preparation method, composition, pharmaceutic preparation and so on. This suggests that Chinese patent of Sunitinib gets the comprehensive protection. If the related companies continue to receive patent protection about Sunitinib, the maln research directions, such as methods for preparations of intermediate, pharmaceutic preparation, different pharmaceutically acceptable salt and its crystal are advised.

关 键 词：舒尼替尼 专利 分析 预警 

分 类 号：R971[医药卫生—药品]